Read the structure, not the headline: this week's deals are priced in promises

The sticker is the least useful number

Look at how this week's deals were announced. Edesa Biotech's licence of its ARDS antibody paridiprubart to Kyorin Pharmaceutical for Japan is billed as worth over $140m. The upfront payment is $12m, and the rest depends on milestones and royalties. Charles River's purchase of Frontage's Exton bioanalysis and DMPK businesses is headlined at about $470m, with up to $75m more in performance-based payments. CorMedix's takeover of substantially all of Heron Therapeutics' assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, is described as about $222.6M upfront, but the consideration also includes shares and contingent earn-outs.

Our view is that the headline figure has become the least informative number in a deal announcement. The useful questions are how much is paid at signing, in what currency, and how much depends on events the buyer does not control.

Structure shows who holds the risk

Acrivon Therapeutics offers the clearest contrast. The oncology-focused biotech bought Aqilion's Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ programme for undisclosed cash, with no future royalties or milestones owed. That is a clean transaction. Aqilion takes certainty and walks away. Acrivon takes all the clinical risk and all the upside of its move into immunology.

Edesa is the opposite case. Most of the value in that Japan licence is contingent, so most of the risk sits with the licensor. Neither structure is wrong, but they are different bets, and a reader who sees only 'over $140m' next to a clean cash purchase will not see the difference.

Announced is not done

Several of these transactions are also well short of completion. ANI Pharmaceuticals announced a proposed offer for Egetis Therapeutics alongside its third-quarter results, aiming to add EMCITATE to its rare disease portfolio, and the deal has not closed. CorMedix expects to close in the first quarter of 2027. Armada Acquisition Corp. III signed to merge with cannabinoid API maker Brains Bioceutical at an implied pre-money equity value of about $750 million, subject to closing conditions. Charles River's deal runs through a consortium structure that first takes Frontage private.

Perspective Therapeutics shows why logos are not terms. It won FDA Fast Track for PSV359 and signed a Merck Keytruda deal, and it reported about $202 million in cash against a Q3 net loss of $32.4 million. The material gives no terms for the Merck arrangement, and without them nobody can judge what it adds.

The strongest counter-argument

The best defence of contingent pricing is that it works. Earn-outs and milestones bridge valuation gaps between a seller confident in its asset and a buyer who wants proof. They keep sellers engaged after signing, and they let a small partner license a single territory, as Edesa has with Japan, without demanding a large cheque for a market it knows less well. Insisting on all-cash certainty would kill deals that make sense.

That is fair, and we are not arguing against contingent structures. We are arguing against reporting them as if they were cash. A $140m licence with $12m upfront and a $470m acquisition with a performance tail are both legitimate, but they are not the same size of commitment. The industry's habit of leading with the biggest number invites readers to treat them as if they were.

What leaders should do

Pharma leaders should treat the structure as the headline and the closing date as part of the price. Deals that are announced but unclosed, or conditional on earn-outs, shareholder processes or a take-private, carry risks that a press-release valuation hides.